|
| Status |
Public on Jul 16, 2022 |
| Title |
Tumor-infiltrating lymphocytes, prognosis and trastuzumab benefit in early-stage breast cancer patients from the FinHER trial |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
The clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer (BC) is not firmly established. We aimed to validate previous prognostic findings in triple negative breast cancer (TNBC) and investigate predictive associations with trastuzumab benefit in HER2 overexpressing disease (HER2+).
|
| |
|
| Overall design |
The Finland Herceptin (FinHER) trial (doi.org/10.1186/ISRCTN76560285) was an adjuvant, phase III study enrolling 1010 early-stage BC patients. Those with HER2+ disease (n=232) were randomized to 9 weeks of trastuzumab or no trastuzumab in addition to chemotherapy. Two pathologists independently quantified TILs from the 935 (92.6%) available slides. Distant disease-free survival (DDFS), overall survival (OS), and interactions with trastuzumab were studied. During the FinHER trial, primary breast cancer specimens were collected from women who had undergone mastectomy or breast-conserving surgery and preserved as formalin-fixed paraffin-embedded (FFPE) tissue blocks. RNA extracted from FFPE specimens with Qiagen's miRNeasy FFPE Kit was processed with SensationPlusTM FFPE Amplification and 3'IVT Labeling Kit. Gene expression profiles were derived from the processed RNA using the PrimeView Human Genome U219 Array Plate on the GeneTitanTM instrument.
|
| |
|
| Contributor(s) |
Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Brown D, Kellokumpu-Lehtinen P, Bono P, Kataja V, Desmedt C, Piccart M, Loibl S, Untch M, Denkert C, Smyth M, Joensuu H, Sotiriou C |
| Citation(s) |
24608200, 19884557, 16495393 |
|
https://doi.org/10.31219/osf.io/qvzxr
|
| |
| Submission date |
Jun 16, 2013 |
| Last update date |
Mar 10, 2024 |
| Contact name |
Christos Sotiriou |
| E-mail(s) |
christos.sotiriou@hubruxelles.be
|
| Phone |
+32 2 541 34 57
|
| Organization name |
Institut Jules Bordet – Université Libre de Bruxelles (ULB)
|
| Lab |
Breast Cancer Translational Research Laboratory J.C. Heuson (ULB 290)
|
| Street address |
Rue Meylemeersch 90
|
| City |
Brussels |
| ZIP/Postal code |
1070 |
| Country |
Belgium |
| |
|
| Platforms (1) |
| GPL13667 |
[HG-U219] Affymetrix Human Genome U219 Array |
|
| Samples (337)
|
|
| Relations |
| BioProject |
PRJNA208626 |
Less...
More...